Brought to you by 
Tesaro raises $40mm in Series B; brings in $60.8mm more
28 Mar 2012
Executive Summary
Tesaro Inc. (supportive cancer therapeutics) has secured $101mm in Series B funding, $40mm of which has already been received through the sale of convertible preferred shares. Kleiner Perkins Caufield & Byers led, joined by founding backer New Enterprise Associates (which committed $40mm of the total amount) and new investors InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management, Leerink Swann, and nine other buyers. Partners from Kleiner Perkins and InterWest have joined the company's board. Proceeds will help bring Tesaro's lead candidate rolapitant (in-licensed from Opko Health last year) through Phase III trials for chemotherapy-induced nausea and vomiting.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tesaro raises $40mm in Series B; brings in $60.8mm more
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice